ArticleFrontiers in immunology2022
Immunotherapeutic Effects of Different Doses of
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Article
- Evaluation of Immunogenicity ofVaccines · 2025Article
- Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant.Virology journal · 2025Article
- Enhanced Immune Responses AgainstIndian journal of microbiology · 2024Article
- Bioinformatics Analysis and Immunogenicity Assessment of the Novel Multi-Stage DNA Vaccine W541 Against Mycobacterium Tuberculosis.Immunity, inflammation and disease · 2024Article
- Research Progress on Liposome Pulmonary Delivery ofJournal of aerosol medicine and pulmonary drug delivery · 2024Review
- Safety and Immunogenicity of anVaccines · 2023Article
- Mechanisms of ag85a/b DNA vaccine conferred immunotherapy and recovery from Mycobacterium tuberculosis-induced injury.Immunity, inflammation and disease · 2023Article
- Preventive effects ofFrontiers in immunology · 2023Article
- B21 DNA vaccine expressing ag85b, rv2029c, and rv1738 confers a robust therapeutic effect against latentFrontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) is a major global public health problem. New treatment methods on TB are urgently demanded. Methods: Ninety-six female BALB/c mice were challenged with 2×10 Results: Compared with the phosphate-buffered saline (PBS) group, the CD4 Conclusions: An MTB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.